Dossier assessment
Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia
Due to disadvantages regarding severe side effects, hint of lesser benefit in comparison with the appropriate comparator therapy
Additional information
Federal Joint Committee (G-BA)
2018-11-22 A G-BA decision was published.
Project details
- Project no.
- A18-33
- Commission
- Commission awarded on 18.05.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Bosutinib (pretreated chronic myelogenous leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Bosutinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed